丹麦晚早产与足月儿培养阴性早发型脓毒症的个体化抗生素疗程(DURATION):多中心、开放标签、随机对照非劣效试验
该研究纳入出生0-3天、胎龄≥35周、出生体重≥2000g且培养阴性疑似早发型脓毒症的晚早产与足月儿,随机分为个体化疗程组与标准5-7天疗程组。个体化组在无感染临床征象且C反应蛋白降至≤30 mg/L后24小时停药。
要点
- 个体化停药策略(无感染征象且CRP≤30 mg/L后24小时停药)感染再入院风险非劣效于标准5-7天疗程。
- 个体化组无严重不良事件,标准组1例(<1%),支持该策略安全性。
核心结论
- 对于培养阴性疑似早发型脓毒症的晚早产与足月儿,临床指导的个体化疗程策略在感染相关再入院方面非劣效于标准5-7天疗程,并将中位疗程缩短至约3天。
研究设计与样本
- 全国性、多中心、开放标签、随机对照非劣效试验,纳入出生0-3天、胎龄≥35周、出生体重≥2000g、培养阴性早发型脓毒症(疑似EOS)的晚早产与足月儿。
- 共811例符合条件,493例(61%)随机分配至个体化组(n=246)或标准组(n=247),按1:1比例。
- 主要终点为细菌感染再入院(非劣效界值4%)和28天内总抗生素疗程(优效性评估),在意向性治疗和符合方案人群中分析;安全性评估所有纳入新生儿。
主要发现
- 符合方案人群结果与意向性治疗分析一致。
关键数值与推荐
- 纳入标准:出生0-3天、胎龄≥35周、出生体重≥2000g,培养阴性早发型脓毒症(疑似EOS),定义为基于感染临床征象或母亲感染危险因素联合C反应蛋白升高且症状在出生后72小时内出现而抗生素治疗持续超过36-48小时。
- 排除标准:符合48小时前停用抗生素标准的新生儿。
- 个体化组停药标准:无感染临床征象且C反应蛋白下降至≤30 mg/L后24小时停用抗生素。
- 标准治疗疗程为5-7天。
- 非劣效界值为4%。
临床怎么用
- 对于培养阴性疑似早发型脓毒症的晚早产与足月儿,可考虑采用临床指导的个体化停药策略:无感染临床征象且CRP降至≤30 mg/L后24小时停用抗生素,以缩短抗生素暴露。
- 该策略在研究中未增加感染再入院风险,但需在监测条件下实施,并排除48小时内可停抗生素的患儿。
局限性
- 开放标签设计可能引入偏倚。
- 研究仅纳入胎龄≥35周、出生体重≥2000g的晚早产与足月儿,结果不能外推至更早产或更低出生体重新生儿。
- 诊断基于培养阴性疑似EOS的临床定义,未涵盖培养阳性脓毒症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Suspicion of early-onset sepsis (EOS) is a major contributor to antibiotic use in late-preterm and term-born neonates. We aimed to evaluate whether a clinically guided, individualised approach to treatment duration could safely reduce antibiotic exposure compared with standard care. METHODS: This nationwide, multicentre, open-label, randomised, controlled, non-inferiority trial included late-preterm and term-born neonates (aged 0-3 days, gestational age 35 weeks or more, birthweight 2000 g or more) with culture-negative early-onset sepsis (probable EOS), defined as continuation of antibiotic treatment beyond 36-48 h based on clinical signs of or maternal risk factors for infection in combination with elevated C-reactive protein and symptom onset less than 72 h after birth. Neonates were ineligible if they met the criteria for discontinuing antibiotics before 48 h. Participants were randomised (1:1) to individualised or standard treatment. In the individualised group, antibiotic treatment was discontinued after 24 h without clinical signs of infection, provided that C-reactive protein was declining to ≤30 mg/L. Standard treatment was 5-7 days. The coprimary outcomes were readmission due to bacterial infection (non-inferiority margin 4%) and total antibiotic duration (superiority assessment), performed on both intention-to-treat and per-protocol populations. Safety was assessed in all included neonates. This study was registered with ClinicalTrials.gov (NCT05329701) and is completed. FINDINGS: Between April 22, 2022, and April 5, 2025, 493 (61%) of 811 eligible neonates were randomly assigned to individualised (n=246) or standard (n=247) duration. Antibiotic therapy was initiated at a median of 22·5 h (IQR 14·4-28·0) after birth in the individualised group and 24·5 h (16·6-28·0) in the standard group. Readmission due to bacterial infection occurred in two (1%) of 246 neonates in the individualised group and one (<1%) of 247 in the standard group (risk difference 0·4% [95% CI -1·5 to 2·6]; pnon-inferiority=0·0032). Median total antibiotic treatment within 28 days was 2·8 days (IQR 2·4-3·4) in the individualised group and 6·8 days (6·6-7·0) in the standard group (difference 4·0 days [95% CI 3·8-4·1]; p<0·0001). No serious adverse events occurred in the individualised group and one (<1%) occurred in the standard group (risk difference -0·4% [95% CI -2·3 to 1·1]). Per-protocol results were consistent. INTERPRETATION: In neonates with probable EOS, a clinically guided, individualised treatment strategy was non-inferior to standard therapy with respect to infection-related readmission and reduced treatment duration to a median of 3 days. These findings support reduced antibiotic use through individualised treatment duration strategies. FUNDING: Copenhagen University Hospital Rigshospitalet Research Fund, Innovation Fund Denmark, and Greater Copenhagen Health Science Partners.
引用
- Carlsen EM, Hansen BM, Dungu KHS, et al. Individualised duration of antibiotic treatment in culture-negative early-onset sepsis in late-preterm and term-born neonates in Denmark (DURATION): a multicentre, open-label, randomised, controlled, non-inferiority trial. Lancet Child Adolesc Health. 2026. PMID: 42302804. doi:10.1016/S2352-4642(26)00118-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。